Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.

HOST
Joshua Davis Kinsey, PharmD
VP, Education
CEimpact

GUEST
Zachary Cox, PharmD
Professor
Lipscomb University College of Pharmacy

Joshua Davis Kinsey has no relevant financial relationships to disclose. 

Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  

CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase this episode and claim your CPE credit, click here. 

CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.
2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.

0.05 CEU/0.5 Hr
UAN: 0107-0000-25-299-H01-P
Initial release date: 10/20/2025
Expiration date: 10/20/2026
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram